 In the current study it is examined whether patients with good risk factors age 75 years, total serum bilirubin 1,5xULN, no history of cardiovascular diseases treated with gemcitabine and erlotinib who developed skin rash of any grade during the first 4 weeks of treatment have a comparable outcome as patients who receive FOLFIRINOX. 